As demand for GLP-1 medications used to treat diabetes and obesity continues to surge, federal health officials are warning consumers that not every product marketed online as “Ozempic” or a similar medication is what it claims to be. The rapid growth of online pharmacies, compounded drug sales, and counterfeit products has created new risks for patients seeking affordable or accessible treatment, prompting renewed concern from regulators and patient safety advocates.

The popularity of medications such as Ozempic, Wegovy, Mounjaro, and Zepbound has grown dramatically over the past several years because of their effectiveness in managing type 2 diabetes and promoting weight loss. However, persistent supply challenges and high out-of-pocket costs have driven many consumers to seek alternatives through telehealth platforms, social media advertisements, and online pharmacies. Health experts say that decision can sometimes come with serious consequences. The U.S. Food and Drug Administration has repeatedly warned consumers about counterfeit versions of GLP-1 medications and unapproved compounded products being sold outside legitimate pharmaceutical supply chains. While compounding pharmacies may legally prepare medications under limited circumstances, compounded drugs are not FDA-approved and are not evaluated by the agency for safety, effectiveness, or quality before they reach patients. The FDA has also stated that some compounders have used salt forms of semaglutide that differ from the active ingredient found in approved medications, raising additional concerns about product quality and effectiveness.

A recent consumer survey conducted by the Alliance for Safe Online Pharmacies (ASOP Global) found widespread confusion among Americans about online medication safety. According to the survey, 38% of U.S. adults reported purchasing prescription medications online. At the same time, 65% incorrectly believed that every online pharmacy is reviewed or approved by the FDA. In reality, the FDA does not certify online pharmacies, and there is no official FDA seal that consumers can use to verify a website’s legitimacy.

That misunderstanding extends to GLP-1 medications themselves. The ASOP Global survey found that many consumers believe compounded or generic versions of GLP-1 drugs have received FDA approval when they have not. The findings suggest that misinformation surrounding these medications is contributing to unsafe purchasing decisions at a time when demand remains exceptionally high. The risks are not simply theoretical. The FDA has received hundreds of reports involving dosing errors and adverse events associated with compounded semaglutide products. Some patients required hospitalization after receiving incorrect doses or using products with unclear instructions. Federal regulators have also warned about counterfeit Ozempic injections entering the U.S. supply chain, with fake products containing unknown ingredients or improperly labeled packaging. The agency advises patients to obtain prescription medications only from state-licensed pharmacies that require a valid prescription and to report suspicious products immediately.

Public health organizations say illegal online pharmacies further complicate the issue. The National Association of Boards of Pharmacy has estimated that the overwhelming majority of websites selling prescription drugs operate outside state and federal laws or pharmacy practice standards. These sites may dispense medications without requiring a prescription, medical evaluation, or ongoing monitoring by a licensed healthcare professional. Experts emphasize that medications used to treat obesity and diabetes require careful clinical oversight. GLP-1 drugs can affect blood sugar, gastrointestinal function, kidney health, and interactions with other medications. Patients may also require dosage adjustments over time, making physician supervision an important part of safe treatment.

For communities of color, the issue carries additional implications. Black and Hispanic adults experience disproportionately higher rates of obesity and type 2 diabetes, yet often face greater barriers to accessing evidence-based treatment because of cost, insurance limitations, and healthcare disparities. Those obstacles can increase the temptation to purchase lower-cost products from unfamiliar online sources. Health equity advocates caution that expanding access to legitimate obesity care must go hand in hand with protecting patients from fraudulent or unsafe products that disproportionately affect underserved populations.

The FDA encourages consumers to verify online pharmacies through trusted resources such as the National Association of Boards of Pharmacy’s Safe Pharmacy program and to avoid websites that sell prescription medications without requiring a prescription. Patients considering GLP-1 therapy are also encouraged to speak with their healthcare provider about approved treatment options and to discuss any concerns about affordability, insurance coverage, or medication availability before seeking alternatives online.

As demand for GLP-1 medications continues to reshape diabetes and obesity care, health officials say patient safety must remain the priority. While these therapies have transformed treatment for millions of Americans, experts warn that purchasing medications from unverified online sources can introduce unnecessary and potentially life-threatening risks. For patients navigating a rapidly changing marketplace, verifying the source of a medication may be just as important as obtaining the prescription itself.

Visit https://healthnothype.org/ to learn more.